Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2423 4-week safety and tolerability in moderate to severe COPD
2010-020891-43Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AZD2423 100 mg oral with Placebo (2 arms). Primary endpoint: Safety and tolerability of AZD2423. Started Aug 2010; status: completed.
02
Drugs
azd2423
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-020891-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020891-43.